曲はいいのに
民度が酷い
それがcmps
民度が酷い
それがcmps
November 7, 2026 at 10:51 AM
曲はいいのに
民度が酷い
それがcmps
民度が酷い
それがcmps
#CMPS Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
https://www.stocktitan.net/news/CMPS/compass-pathways-completes-comp360-psilocybin-new-drug-application-08jxd0bkfquw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-completes-comp360-psilocybin-new-drug-application-08jxd0bkfquw.html?utm_source=stocktitan-bluesky&utm_medium=social
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 9, 2026 at 11:30 AM
#CMPS Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
https://www.stocktitan.net/news/CMPS/compass-pathways-completes-comp360-psilocybin-new-drug-application-08jxd0bkfquw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-completes-comp360-psilocybin-new-drug-application-08jxd0bkfquw.html?utm_source=stocktitan-bluesky&utm_medium=social
$CMPS: investor conference presentation Nov 11 confirmed.
Hub: https://www.merlintrader.com/compass-pathways-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
Hub: https://www.merlintrader.com/compass-pathways-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
November 9, 2026 at 6:01 PM
$CMPS: investor conference presentation Nov 11 confirmed.
Hub: https://www.merlintrader.com/compass-pathways-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
Hub: https://www.merlintrader.com/compass-pathways-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
#BiotechHangout: Brian Skorney, Adam Feuerstein, Paul Matteis, Yaron Werber on election results, company news: #$VRTX pove, #$RVMD Rasonque, #$NBIX Vykat, #$MDGL whistleblower, Usona/$CMPS, #$SNY stops #$NRIX STAT6 degrader, #$NVS Zolgensma, earnings: #$AMGN, #$ONC, data: #AHA26 & #ASH26 bit.ly/3Wu4F3c
November 6, 2026 at 2:01 PM
#BiotechHangout: Brian Skorney, Adam Feuerstein, Paul Matteis, Yaron Werber on election results, company news: #$VRTX pove, #$RVMD Rasonque, #$NBIX Vykat, #$MDGL whistleblower, Usona/$CMPS, #$SNY stops #$NRIX STAT6 degrader, #$NVS Zolgensma, earnings: #$AMGN, #$ONC, data: #AHA26 & #ASH26 bit.ly/3Wu4F3c
$CMPS: Compass Pathways held $444.0M in cash at Sept 30 with runway guided into 2028; Q3 operating loss was $56.4M. Not investment advice.
https://www.merlintrader.com/compass-pathways-stock-hub/
https://www.merlintrader.com/compass-pathways-stock-hub/
November 8, 2026 at 11:00 AM
$CMPS: Compass Pathways held $444.0M in cash at Sept 30 with runway guided into 2028; Q3 operating loss was $56.4M. Not investment advice.
https://www.merlintrader.com/compass-pathways-stock-hub/
https://www.merlintrader.com/compass-pathways-stock-hub/
#$NVCR down 4% premarket: FDA rejects Optune Mya for brain cancer from lung tumors (benefit unclear, safe). #$IBRX down 13%: Q3 sales $48.7M miss $59M est. #$CMPS files FDA app for psilocybin depression treatment, strong data, possible early 2027 launch. notreload.xyz/wall-street-...
November 9, 2026 at 1:31 PM
#$NVCR down 4% premarket: FDA rejects Optune Mya for brain cancer from lung tumors (benefit unclear, safe). #$IBRX down 13%: Q3 sales $48.7M miss $59M est. #$CMPS files FDA app for psilocybin depression treatment, strong data, possible early 2027 launch. notreload.xyz/wall-street-...
#CMPS Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-under-9i2lx62jwffp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-under-9i2lx62jwffp.html?utm_source=stocktitan-bluesky&utm_medium=social
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 5, 2026 at 9:30 PM
#CMPS Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-under-9i2lx62jwffp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-under-9i2lx62jwffp.html?utm_source=stocktitan-bluesky&utm_medium=social
#$CMPS — Compass Pathways expects to file the COMP360 NDA in TRD within two weeks.
Cash $444.0M at Sep 30; launch targeted H1 2027, subject to FDA approval and scheduling.
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
Cash $444.0M at Sep 30; launch targeted H1 2027, subject to FDA approval and scheduling.
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
November 4, 2026 at 3:05 PM
#$CMPS — Compass Pathways expects to file the COMP360 NDA in TRD within two weeks.
Cash $444.0M at Sep 30; launch targeted H1 2027, subject to FDA approval and scheduling.
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
Cash $444.0M at Sep 30; launch targeted H1 2027, subject to FDA approval and scheduling.
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
Compass Pathways (#$CMPS) completed its NDA submission for COMP360 psilocybin in treatment-resistant depression. FDA acceptance and approval still pending.
prismmarketview.com/compass-path...
prismmarketview.com/compass-path...
Compass Pathways Takes COMP360 Psilocybin to FDA, Eyes 2027 Launch for Treatment-Resistant Depression
Key Points Compass Pathways completed its New Drug Application submission for COMP360 psilocybin in treatment-resistant depression. The application draw
prismmarketview.com
November 9, 2026 at 4:14 PM
Compass Pathways (#$CMPS) completed its NDA submission for COMP360 psilocybin in treatment-resistant depression. FDA acceptance and approval still pending.
prismmarketview.com/compass-path...
prismmarketview.com/compass-path...
#CMPS Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
https://www.stocktitan.net/news/CMPS/compass-pathways-to-participate-in-stifel-2026-healthcare-conference-mh4wwfcafbwd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-to-participate-in-stifel-2026-healthcare-conference-mh4wwfcafbwd.html?utm_source=stocktitan-bluesky&utm_medium=social
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 11:30 AM
#CMPS Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
https://www.stocktitan.net/news/CMPS/compass-pathways-to-participate-in-stifel-2026-healthcare-conference-mh4wwfcafbwd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-to-participate-in-stifel-2026-healthcare-conference-mh4wwfcafbwd.html?utm_source=stocktitan-bluesky&utm_medium=social
Compass Pathways $CMPS reported Q3 2026 EPS of -$0.31, beating the -$0.34 estimate by 8.8%. Revenue was $0. No analyst estimate was published for revenue.
https://fundspec.ai/s/CMPS/earnings
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/CMPS/earnings
Track what company insiders are actually buying and selling.
November 3, 2026 at 11:38 AM
Compass Pathways $CMPS reported Q3 2026 EPS of -$0.31, beating the -$0.34 estimate by 8.8%. Revenue was $0. No analyst estimate was published for revenue.
https://fundspec.ai/s/CMPS/earnings
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/CMPS/earnings
Track what company insiders are actually buying and selling.
$CMPS session breakout running hot this session, verticals can fade fast on the open. Tapeboard scanner tracking the move. Down 26.4% to $8.52 from… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cmps-bk-dn-watch&utm_term=scanner&s=CMPS
November 2, 2026 at 6:51 PM
$CMPS session breakout running hot this session, verticals can fade fast on the open. Tapeboard scanner tracking the move. Down 26.4% to $8.52 from… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cmps-bk-dn-watch&utm_term=scanner&s=CMPS
$CMPS down 17.6% to $9.53 from $11.57 on 3.06M shares in the session. Compass Pathways released a treatment-resistant depression survey with the De… https://tapeboard.com/go/bsky/research/CMPS?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cmps-bk-dn-watch&utm_term=research
November 2, 2026 at 6:19 PM
$CMPS down 17.6% to $9.53 from $11.57 on 3.06M shares in the session. Compass Pathways released a treatment-resistant depression survey with the De… https://tapeboard.com/go/bsky/research/CMPS?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cmps-bk-dn-watch&utm_term=research
$CMPS down 7.8% to $10.66 on 1,220,236 shares versus a $11.57 prior close. Tapeboard chart is up, scanner is tracking the move. No read on it yet… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cmps-bk-dn-scanner&utm_term=scanner&s=CMPS
November 2, 2026 at 4:24 PM
$CMPS down 7.8% to $10.66 on 1,220,236 shares versus a $11.57 prior close. Tapeboard chart is up, scanner is tracking the move. No read on it yet… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cmps-bk-dn-scanner&utm_term=scanner&s=CMPS
Compass Pathways #$CMPS reported Q3 2026 results.
Net loss of $9.8M, $444.0M in cash, and the final NDA submission is to be filed in the next two weeks.
Mon close $8.41: below SMA50, below SMA200, RSI 28.
Hub: www.merlintrader.com/compass-path...
Not investment advice.
Net loss of $9.8M, $444.0M in cash, and the final NDA submission is to be filed in the next two weeks.
Mon close $8.41: below SMA50, below SMA200, RSI 28.
Hub: www.merlintrader.com/compass-path...
Not investment advice.
CMPS Stock: Compass Pathways News, COMP360 NDA & Launch
Compass Pathways stock news and analysis: the COMP360 NDA, controlled and open-label evidence, cash and the conditions for a supervised launch for CMPS holders.
www.merlintrader.com
November 3, 2026 at 12:08 PM
Compass Pathways #$CMPS reported Q3 2026 results.
Net loss of $9.8M, $444.0M in cash, and the final NDA submission is to be filed in the next two weeks.
Mon close $8.41: below SMA50, below SMA200, RSI 28.
Hub: www.merlintrader.com/compass-path...
Not investment advice.
Net loss of $9.8M, $444.0M in cash, and the final NDA submission is to be filed in the next two weeks.
Mon close $8.41: below SMA50, below SMA200, RSI 28.
Hub: www.merlintrader.com/compass-path...
Not investment advice.
#$CMPS weekly close $11.57 (+3.5% w/w), below SMA50 $12.91 / above SMA200 $10.40, RSI 45.6. Range $10.72-$12.50.
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
CMPS Stock: Compass Pathways News, COMP360 NDA & Launch
Compass Pathways stock news and analysis: the COMP360 NDA, controlled and open-label evidence, cash and the conditions for a supervised launch for CMPS holders.
www.merlintrader.com
November 2, 2026 at 10:23 AM
#$CMPS weekly close $11.57 (+3.5% w/w), below SMA50 $12.91 / above SMA200 $10.40, RSI 45.6. Range $10.72-$12.50.
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
CMPS Stock Hub: Compass Pathways News, COMP360 NDA and Launch Readiness
www.merlintrader.com/compass-path...
#CMPS Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-third-quarter-2026-financial-results-and-qbrrurw8csji.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-third-quarter-2026-financial-results-and-qbrrurw8csji.html?utm_source=stocktitan-bluesky&utm_medium=social
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 3, 2026 at 11:30 AM
#CMPS Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-third-quarter-2026-financial-results-and-qbrrurw8csji.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CMPS/compass-pathways-announces-third-quarter-2026-financial-results-and-qbrrurw8csji.html?utm_source=stocktitan-bluesky&utm_medium=social
$CMPS — CMPS experienced a significant volume-driven price breakdown on competitive fears, breaking below key moving averages.
Price broke below 50-day and 200-day SMAs.
https://market-scanner.net/tickers/CMPS.US
#ai #trading
Price broke below 50-day and 200-day SMAs.
https://market-scanner.net/tickers/CMPS.US
#ai #trading
CMPS.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
November 2, 2026 at 11:26 PM
$CMPS — CMPS experienced a significant volume-driven price breakdown on competitive fears, breaking below key moving averages.
Price broke below 50-day and 200-day SMAs.
https://market-scanner.net/tickers/CMPS.US
#ai #trading
Price broke below 50-day and 200-day SMAs.
https://market-scanner.net/tickers/CMPS.US
#ai #trading
🚨 $CMPS
On November 3, 2026, COMPASS Pathways plc issued a press release announcing the Company's financial results for the three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K (including ...
On November 3, 2026, COMPASS Pathways plc issued a press release announcing the Company's financial results for the three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K (including ...
SEC Filing: CMPS
Click to view the official SEC document.
www.sec.gov
November 3, 2026 at 1:22 PM
🚨 $CMPS
On November 3, 2026, COMPASS Pathways plc issued a press release announcing the Company's financial results for the three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K (including ...
On November 3, 2026, COMPASS Pathways plc issued a press release announcing the Company's financial results for the three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1. The information in Item 2.02 of this Form 8-K (including ...
📊 Stock movers right now:
INO: $1.97 (+227.0%)
CLRO: $5.38 (+57.8%)
JAGX: $0.87 (-46.4%)
VCIG: $4.08 (+34.2%)
CMPS: $7.71 (-33.4%)
More: https://suggestionbox.live/planet-markets
INO: $1.97 (+227.0%)
CLRO: $5.38 (+57.8%)
JAGX: $0.87 (-46.4%)
VCIG: $4.08 (+34.2%)
CMPS: $7.71 (-33.4%)
More: https://suggestionbox.live/planet-markets
November 2, 2026 at 7:00 PM
📊 Stock movers right now:
INO: $1.97 (+227.0%)
CLRO: $5.38 (+57.8%)
JAGX: $0.87 (-46.4%)
VCIG: $4.08 (+34.2%)
CMPS: $7.71 (-33.4%)
More: https://suggestionbox.live/planet-markets
INO: $1.97 (+227.0%)
CLRO: $5.38 (+57.8%)
JAGX: $0.87 (-46.4%)
VCIG: $4.08 (+34.2%)
CMPS: $7.71 (-33.4%)
More: https://suggestionbox.live/planet-markets
What a cookie banner offers shapes what we choose. In a small experiment (40 people; Nouwens et al., CHI 2020), removing “Reject” from the first screen raised consent by 22–23 points. “Accept all” is partly a result of design, not only of what we value.
#privacy #darkpatterns
#privacy #darkpatterns
Dark Patterns after the GDPR: Scraping Consent Pop-ups and Demonstrating their Influence
New consent management platforms (CMPs) have been introduced to the web to conform with the EU's General Data Protection Regulation, particularly its requirements for consent when companies collect an...
arxiv.org
November 4, 2026 at 4:31 PM
What a cookie banner offers shapes what we choose. In a small experiment (40 people; Nouwens et al., CHI 2020), removing “Reject” from the first screen raised consent by 22–23 points. “Accept all” is partly a result of design, not only of what we value.
#privacy #darkpatterns
#privacy #darkpatterns
$SUPN merged with Indivior, expanding CNS portfolio to 11 therapies. Scale and liquidity up; $650M debt funds $1B payout. $AHCO $MDGL $JAGX $BDMD $CMPS $EBS $NIKI $GANX $TLSI $BVS
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 11/03/26
export-download.canva.com
November 3, 2026 at 1:40 PM
$SUPN merged with Indivior, expanding CNS portfolio to 11 therapies. Scale and liquidity up; $650M debt funds $1B payout. $AHCO $MDGL $JAGX $BDMD $CMPS $EBS $NIKI $GANX $TLSI $BVS
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Psychedelic Alpha reports Usona has likely filed an NDA for psilocybin in major depression, intensifying competition with #$CMPS and other developers. #$DFTX, #$HELP, #$GHRS notreload.xyz/xy/usona-psi...
Usona Psilocybin NDA Filing Intensifies Competition
Usona’s potential FDA filing for psilocybin makes the competitive landscape more real for Compass, Definium, Helus Pharma and GH Research, analyst says.
notreload.xyz
November 2, 2026 at 8:37 PM
Psychedelic Alpha reports Usona has likely filed an NDA for psilocybin in major depression, intensifying competition with #$CMPS and other developers. #$DFTX, #$HELP, #$GHRS notreload.xyz/xy/usona-psi...